{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:54:20Z","timestamp":1788173660168,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Visual complaint is not very uncommon in chronic myeloid leukemia (CML) patients. Our study aims to evaluate the visual pathway using visual evoked potential (VEP) in cases of CML at the time of diagnosis and 6 weeks after tyrosine kinase therapy, to find out treatment impact in asymptomatic as well as symptomatic individuals and compare it with the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>This is an analytical cross-sectional study. The study group comprised 20 newly diagnosed cases of CML and 20 age- and sex-matched healthy control population. A thorough history and clinical examination with detailed ophthalmological studies, including VEP, were done. Cases who had VEP abnormalities were then followed-up after 6 weeks post-Imatinib therapy and underwent repeat investigations, including VEP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      VEP in cases was significantly deranged (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), where 15 patients (75%) had abnormalities in VEP compared to 3 (15%) in control. Post 6 weeks chemotherapy, Out of 10 cases that were followed up, 7 patients had achieved hematological remission with normal VEP finding (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02). Simultaneously, an increase in hemoglobin (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002) and reduction in total leukocyte count (TLC) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004) were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Considerable evidence appear to support the notion that CML patients have a higher prevalence of ophthalmic manifestations as compared to the general population, which can be screened earlier with objective tests like VEP. Concurrently, hematological parameters and VEP showed derangement at the time of diagnosis. After 6 weeks of Imatinib treatment, the improvement in VEP can then be attributed to a reduction in TLC. Hence it can be deduced that VEP has paramount importance in the early identification of ophthalmic manifestations, which are reversible with timely treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ojo.ojo_245_22","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:54:21Z","timestamp":1716558861000},"page":"489-494","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of visual evoked potential in chronic myeloid leukemias"],"prefix":"10.4103","volume":"16","author":[{"given":"Avishkar","family":"Agrawal","sequence":"first","affiliation":[{"name":"Department of Cardiology, AIIMS, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, MAMC, LNJP Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranvijay","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medicine, MAMC, LNJP Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaharlal","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, GNEC, MAMC, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Medicine, MAMC, LNJP Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"R1-20240908","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","article-title":"Diagnosis and treatment of chronic myeloid leukemia in 2015","volume":"90","author":"Thompson","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"R2-20240908","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-20240908","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JGO.2015.002667","article-title":"Chronic myeloid leukemia in India","volume":"3","author":"Ganesan","year":"2017","journal-title":"J Glob Oncol"},{"key":"R4-20240908","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"R5-20240908","doi-asserted-by":"crossref","first-page":"12","DOI":"10.31661\/gmj.v6i1.702","article-title":"History of leukemia: Diagnosis and treatment from beginning to now","volume":"6","author":"Mehranfar","year":"2017","journal-title":"Galen Med J"},{"key":"R6-20240908","doi-asserted-by":"crossref","first-page":"e2014010","DOI":"10.4084\/mjhid.2014.010","article-title":"A critical history of chromic myeloid leukemia","volume":"6","author":"Baccarani","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R7-20240908","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archopht.1989.01070010715033","article-title":"Ophthalmic manifestations of leukemia","volume":"107","author":"Schachat","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"R8-20240908","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1200\/JCO.1989.7.10.1528","article-title":"A prospective ophthalmic evaluation of patients with acute myeloid leukemia: Correlation of ocular and hematologic findings","volume":"7","author":"Karesh","year":"1989","journal-title":"J Clin Oncol"},{"key":"R9-20240908","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000073077","article-title":"Ocular involvement in leukemia \u2013 A study of 288 cases","volume":"217","author":"Reddy","year":"2003","journal-title":"Ophthalmologica"},{"key":"R10-20240908","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4103\/0301-4738.169789","article-title":"Ophthalmic manifestations of acute and chronic leukemias presenting to a tertiary care center in India","volume":"63","author":"Koshy","year":"2015","journal-title":"Indian J Ophthalmol"},{"key":"R11-20240908","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/1596-3519.188887","article-title":"Ocular manifestations in leukemia and myeloproliferative disorders and their association with hematological parameters","volume":"15","author":"Dhasmana","year":"2016","journal-title":"Ann Afr Med"},{"key":"R12-20240908","first-page":"304","article-title":"Pars Plana vitrectomy in chronic myelogenous leukemia with vitreous hemorrhage","volume":"32","author":"Hasanreiso\u011flu","year":"1988","journal-title":"Jpn J Ophthalmol"},{"key":"R13-20240908","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0145-2126(92)90144-V","article-title":"Isolated optic nerve involvement in chronic myeloid leukemia","volume":"16","author":"Costagliola","year":"1992","journal-title":"Leuk Res"},{"key":"R14-20240908","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0002-9394(02)01956-6","article-title":"Peripheral retinal nonperfusion associated with chronic myeloid leukemia","volume":"135","author":"Nobacht","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R15-20240908","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4103\/0974-9233.90143","article-title":"Visual disturbance as the first symptom of chronic myeloid leukemia","volume":"18","author":"Huang","year":"2011","journal-title":"Middle East Afr J Ophthalmol"},{"key":"R16-20240908","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/JDRNTRUHS.JDRNTRUHS_6_18","article-title":"Atypical presentation of chronic myeloid leukemia with visual disturbance","volume":"7","author":"Chennamaneni","year":"2018","journal-title":"J Dr NTR Univ Health Sci"},{"key":"R17-20240908","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/2278-330X.187593","article-title":"Summary of the published Indian data on chronic myeloid leukemia","volume":"5","author":"Singhal","year":"2016","journal-title":"South Asian J Cancer"},{"key":"R18-20240908","first-page":"60","article-title":"Optic neuropathy in the context of leukemia or lymphoma: Diagnostic approach to a neuro-oncologic emergency","volume":"4","author":"Myers","year":"2017","journal-title":"Neurooncol Pract"},{"key":"R19-20240908","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/archopht.1988.01060130708030","article-title":"Optic neuropathy in chronic lymphocytic leukemia","volume":"106","author":"Currie","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"R20-20240908","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1590\/S1516-31801996000100005","article-title":"Chronic myeloid leukemia (CML): Prognostic factors and survival analysis","volume":"114","author":"Braga","year":"1996","journal-title":"Sao Paulo Med J"},{"key":"R21-20240908","first-page":"109","article-title":"Hematological and molecular response evaluation of CML patients on imatinib","volume":"55","author":"Gupta","year":"2007","journal-title":"J Assoc Physicians India"},{"key":"R22-20240908","doi-asserted-by":"crossref","first-page":"1835091","DOI":"10.1155\/2019\/1835091","article-title":"Effect of imatinib on bone marrow morphology and angiogenesis in chronic myeloid leukemia","volume":"2019","author":"Pandey","year":"2019","journal-title":"Adv Hematol"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_245_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:48:13Z","timestamp":1787770093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_245_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_245_22","relation":{},"ISSN":["0974-620X","0974-7842"],"issn-type":[{"value":"0974-620X","type":"print"},{"value":"0974-7842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"2022-08-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}